vimarsana.com
Home
Live Updates
Four-year follow up data for Roche's Evrysdi show continued
Four-year follow up data for Roche's Evrysdi show continued
Four-year follow up data for Roche's Evrysdi show continued increase in number of children with a severe form of spinal muscular atrophy (SMA) able to sit, stand and walk
Data from ongoing FIREFISH study confirm long-term efficacy and safety profile of Evrysdi in children with Type 1 SMANinety-one percent of children were alive at month 48More than 95% maintained the...
Related Keywords
Switzerland ,
Japan ,
United Kingdom ,
United States ,
London ,
City Of ,
America ,
British ,
Kirti Pandey ,
Loren Kalm ,
Levi Garraway ,
Birgit Masjost ,
Nathalie Altermatt ,
Bruno Eschli ,
Gerard Tobin ,
Sabine Borngr ,
Giovanni Baranello ,
British Pharmacological Society ,
Roche Group ,
Toddler Development Third Edition ,
Drug Administration ,
Research Clinical Care Meeting ,
Head Of Global Product Development ,
Society For Medicines Research ,
Genentech ,
Office Of Orphan Products Development ,
European Medicines Agency ,
Roche Group Media Relations ,
Institute Of Child Health Hospital ,
Gross Motor Scale ,
Bayley Scales ,
Hammersmith Infant Neurological Examination ,
Clinical Care Meeting ,
Ormond Street Institute ,
Child Health ,
Great Ormond Street Hospital ,
Chief Medical Officer ,
Global Product ,
Orphan Drug Designation ,
Drug Discovery ,
Medicines Research ,
Orphan Products Development ,
Drug Designation ,
Muscular Atrophy ,
Spinal Muscular Atrophy ,
Dow Jones Sustainability Indices ,
Chugai Pharmaceutical ,